Management of Hepaticojejunostomy Complications

Initial Assessment and Diagnosis

The American Association for the Study of Liver Diseases recommends obtaining liver function tests, including bilirubin, AST, ALT, alkaline phosphatase, and GGT, to assess cholestasis severity in patients with suspected hepaticojejunostomy complications 3
Inflammatory markers, such as CBC, CRP, and procalcitonin, should be obtained if infection is suspected in patients with hepaticojejunostomy complications 4
Transabdominal ultrasound is recommended as the first-line imaging modality to identify bile duct dilation, fluid collections, and anastomotic strictures in patients with suspected hepaticojejunostomy complications 4
CT with IV contrast is recommended for critically ill patients or when ultrasound is inconclusive in patients with suspected hepaticojejunostomy complications 4

Anastomotic strictures occur in 10-20% of cases at a median time of 11-30 months postoperatively, and the American College of Surgeons recommends percutaneous transhepatic cholangiography as the primary treatment modality for focal anastomotic strictures 1, 3
Risk factors for stricture formation include associated vascular injury, level of bile duct injury, sepsis/peritonitis, and postoperative bile leakage, according to the Society of Surgical Oncology 1, 2
The American Gastroenterological Association recommends starting broad-spectrum antibiotics immediately, such as piperacillin/tazobactam, in patients with recurrent cholangitis 4
Biliary decompression via PTC is essential for source control in patients with recurrent cholangitis, according to the American Association for the Study of Liver Diseases 3

The Society of Surgical Oncology recommends a multidisciplinary approach at a tertiary hepatobiliary center for the management of failed hepaticojejunostomy, with first-line options including repeat hepaticojejunostomy and percutaneous biliary interventions 2, 5
The American College of Surgeons recommends avoiding delayed referral to hepatobiliary centers for complex complications, as primary repair attempts by non-expert surgeons have significantly higher failure rates and mortality 5, 4

The American Association for the Study of Liver Diseases reports that overall clinical success, defined as the absence of incapacitating biliary symptoms, is achieved in 89% of patients with appropriate management 1
The Society of Surgical Oncology reports that long-term patency of 80-90% is expected when hepaticojejunostomy is performed correctly 1
Biliary cirrhosis develops in 2.4-10.9% of cases, particularly with associated vascular injury, according to the American College of Surgeons 1
The American College of Surgeons reports that BDI-related mortality ranges from 1.8-4.6% 1